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Summary Breast cancer is commonly treated with anti-
estrogens or aromatase inhibitors, but resistant disease
eventually develops and new therapies for such resistance
are of great interest. We have previously isolated several
tamoxifen-resistant variant sub-lines of the MCF-7 breast
cancer cell line and provided evidence that they arose from
expansion of pre-existing minor populations. We have
searched for therapeutic agents that exhibit selective growth
inhibition of the resistant lines and here investigate 2,6-bis
(pyridin-3-ylmethylene)-cyclohexanone (RL90) and 2,6-bis
(pyridin-4-ylmethylene)-cyclohexanone (RL91). We found
that two of the tamoxifen-resistant sub-lines (TamR3 and
TamC3) unexpectedly showed increased sensitivity to RL90
and RL91. We utilized growth inhibition assays, flow
cytometry and immunoblotting to establish a mechanistic
basis for their action. Treated sensitive cells showed S-phase
selective DNA damage, as detected by histone H2AX
phosphorylation. Cellular responses were similar to those
induced by the topoisomerase I poison camptothecin.
Although IC50 values of camptothecin, RL90, RL91 were
correlated, studies with purified mammalian topoisomerase I
suggested that RL90 and RL91 differed from camptothecin
by acting as catalytic topoisomerase I inhibitors. These drugs
provide a platform for the further development of DNA
damaging drugs that have selective effects on tamoxifen
resistant breast cancer cells. The results also raise the
question of whether clinical topoisomerase I poisons such
as irinotecan and topotecan might be active in the treatment
of some types of tamoxifen-resistant cancer.
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Introduction
Breast cancer growth, at least in its early stages, is known
to be driven by the steroid hormone estrogen and one of the
main methods of treating estrogen receptor positive (ER+)
breast cancer apart from surgery is to block the growth
promoting action of estrogen. This is achieved either by
blocking the downstream action with anti-estrogens such as
tamoxifen or by reducing the concentration of circulating
estrogen through oophorectomy or treatment with an
aromatase inhibitor. While such approaches are often
effective in ER+breast cancer, they may also lead to the
emergence of aggressive tamoxifen-resistant tumors that
pose a major barrier to successful disease management [1]
and new therapeutic approaches are required. We have
previously developed a series of anti-estrogen resistant
sub-lines of the MCF-7 human breast cancer cell line
and used them to search for potential therapeutic agents
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that inhibit the proliferation of these resistant cells. We first
investigated rapamycin, an inhibitor of the mTOR (mamma-
lian target of rapamycin) pathway [2] and found that the
emergence of tamoxifen resistance appeared to be accompa-
nied by resistance to rapamycin. The phosphoinositide-3-
kinase (PI3K) and mTOR signaling pathway [3] is an
important potential target for anti-estrogen resistant breast
cancer [4] but our investigation of two inhibitors (NVP-
BEZ235 and GSK2126458) found tamoxifen-resistant lines
to be cross-resistant [5, 6]. We report here a study of two
heterocyclic cyclohexanone derivatives, RL90 and RL91
(structures in Fig. 1), which we have found unexpectedly to
selectively inhibit growth of two of these sub-lines.
The resistant MCF-7 sub-lines was developed by
culturing the parental line for prolonged periods either
in the presence of increasing concentrations of tamox-
ifen to block estrogen action, or in the absence of
estrogen to mimic the action of oophorectomy or
treatment with aromatase inhibitors [5]. Both treatments
led to initial growth inhibition followed by outgrowth of
resistant sub-lines that proliferated under restrictive con-
ditions. Analysis of the resistant sub-lines indicated that
they were derived by expansion of pre-existing minor
populations in the parental MCF-7 population, a conclu-
sion in agreement with other studies [7, 8]. The cell lines
varied not only in their expression of ER, PR
(progesterone receptors) and epidermal growth factor
receptor-2 (EGFR2; HER2) but also in their utilization
of intracellular signaling pathways [5, 6, 9]. For instance,
two of the lines, TamR3 (isolated in the presence of
tamoxifen) and TamC3 (isolated in the absence of
estrogen) showed low phosphorylation of AKT/PKB
(protein kinase B) indicative of utilization of alternative
pathway other than the PI3K for growth.
RL90 and RL91 are cyclohexanone derivatives that have
previously been reported to inhibit the growth of the ER-
negative MDA-MB-231 line weakly and of the ER-
negative HER2+ SKBr3 cell line strongly [10]. They are
related structurally to BMHPC (Fig. 1), which binds to type
II estrogen binding sites, and to curcumin, which has
multiple cellular targets including estrogen receptors [11,
12]. In this study we have used the ER-positive MCF-7 cell
line and two of its hormone-resistant sub-lines to test the
hypothesis that RL90 and RL91 selectively inhibit the
growth of antiestrogen-resistant cells. We have also
explored the mechanism of anti-proliferative action of
RL90 and RL91 in MCF-7 and its sub-lines, using the
MDA-MB-231 and SKBr3 breast cancer cell lines for
comparison. The results suggest unexpectedly that the
enzyme topoisomerase I is a potential target for RL90 and
RL91 action raising the question of whether this enzyme is




Culture conditions have been described previously [5];
MCF-7, MDA-MB-231 and SKBr3 were purchased from
the American Type Culture Collection (ATCC). The TamR7
cell line was established by culturing MCF-7 cells in the
presence of progressively increasing concentrations of
tamoxifen (10−7 to 3×10−6 M in DMSO) and then
maintaining them for >15 months in 3×10−6 M tamoxifen.
The TamR3 and TamR6 cell lines were generated by
growth of MCF-7 cells in phenol-red-free RPMI containing
10% charcoal-stripped fetal bovine serum (Invitrogen,
Auckland, NZ), over a period of 3 months to progressively
increasing concentrations of tamoxifen (10−9 to 10−6 M in
ethanol) and then maintaining them for >15 months in
10−6 M tamoxifen. The TamC3 and TamC6 cell lines were
generated by exposure of MCF-7 cells for >16 months to
the above growth medium but lacking tamoxifen. All
experiments were carried out on cells grown in their
respective growth media but without tamoxifen.
Chemicals and reagents
Propidium iodide, tamoxifen, camptothecin, doxorubicin,
bicinchoninic acid (BCA) and tamoxifen were from
Sigma (Auckland, NZ). RL90 and RL91 were synthesized
according to published protocols [10]. The CK2 inhibitor
4,5,6,7-tetrabromobenzotriazole, 4,5,6,7-tetrabromo-2-





Fig. 1 Structures of RL90, RL91, BMHPC and curcumin
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Germany) and the CK2 activator 1-ethyl-4,5-dicarbamoy-
limidazole [13] was synthesized according the published
methods [14].
Cell proliferation assay
Cells (3,000 per well) were seeded in 96 well plates in the
presence of varying concentrations of inhibitors and after
incubation for 3 days, proliferation was measured using the
sulforhodamine B colorimetric assay [15].
Flow cytometric analysis
Cells (106 cells per well) were grown in 6 well plates and
incubated with inhibitors for the indicated time. Cells were
harvested, washed and resuspended in 1 ml of blocking
buffer (1% FCS/PBS), and incubated with antibody to γ-
H2AX (phosphorylated Ser139) (Millipore, USA) in block-
ing buffer (1:500 dilution) at room temperature for 2 h.
Cells were washed, incubated with goat anti-mouse Alex
488 Fab fragment secondary antibody (Invitrogen, New
Zealand) (1:400 in blocking buffer for 1 h, at room
temperature; dark), washed and resuspended in 1 ml of
blocking buffer containing RNase (1 μg/ml) and propidium
iodide (PI) (10 μg/ml) for 30 min at room temperature.
Cells were analyzed in a Becton Dickinson LSRII and
profiles were analyzed with ModFit LT 3 software.
DNA topoisomerase I assay
Relaxation of DNA by topoisomerase I was determined
using a topoisomerase I drug screening kit (TopoGEN Inc.,
USA). Reactions were assembled on ice with 0.25 μg of
plasmid and recombinant human topoisomerase I (1 unit for
DNA cleavage or 0.25 units for DNA relaxation assay) and
drug. Samples were incubated (30 min at 37°C) and
prewarmed 1% SDS and 50 ng/ml proteinase K was added
to terminate the reaction. Samples were resolved on 1%
TBE (89 mM Tris base, 89 mM boric acid, 2 mM EDTA)
agarose gels at 45 V for 3 h with or without 1 μg/mL
ethidium bromide. After electrophoresis, the gels without
ethidium were stained with ethidium bromide (1 μg/mL).
Western blotting
Cells were grown to logarithmic-phase, washed twice with
ice-cold PBS, and lysed in SDS lysis buffer (Cell Signaling
Technology, Danvers, MA). Protein concentration was
quantified using BCA. Cell lysates containing 20 μg of
protein were separated by SDS-PAGE gel electrophoresis,
and transferred to PVDF membranes (Millipore).
Membranes were immunoblotted with antibodies against
topoisomerase I (Santa Cruz technology), tubulin (Sigma),
ABCG2 (Abcam), CK2 and actin (both from Millipore),
using SuperSignal West Pico (Thermo Scientific, Waltham,
MA). Antibody reactivity was visualized using the
chemiluminescence detection system by Fujifilm Las-3000.
Statistical analysis
Analysis was performed in PASW (SPSS v18, SPSS
Corporation) applying Dunnett’s T2 correction to measure
drug effects on proliferation. Correlation analysis was
performed in Sigma Plot.
Results
Effects of RL90 and RL91 on cell proliferation
The effects of RL90 and RL91 on the proliferation of
MCF-7 parental and sub-lines are shown in Fig. 2
(Fig. S1A, B and C). Since all lines were ER+, comparison
was also made with the ER- lines SKBr3 and MDA-MB-231.
As shown in Fig. 2, growth inhibition was greatest with the
MCF-7 sub-lines TamC3 and TamR3. Curcumin was also
tested for comparison (Fig. 2); it was much less potent than
RL90 or RL91 but the IC50 values were nevertheless
significantly correlated (r>0.95; P<0.01) to those of RL90
and RL91.
Induction of DNA damage by RL90 and RL91
Since both RL90 and RL91 have been reported to induce
G2/M cell cycle arrest and apoptosis in SKBr3 cells [10],
we tested for DNA damage in the MCF-7 sub-lines by
measuring γ-phosphorylation of H2AX. Comparison of
flow cytometry profiles following drug treatment for 16 h
showed S-phase specific DNA damage in the TamR3 and
TamC3 lines (Fig. 3a). Treated cells showed an increase in
G2/M-phase cells but only a small decrease in G1-phase
cells (Suppl. Fig. S2A), consistent with a lack of induced
G1 arrest. Time course experiments using TamC3 showed
that DNA damage was evident 2 h after treatment and
continued for more than 24 h (Fig. 3b). The profiles also
showed a minor population of cells with very high staining
for γ-phosphorylation of H2AX (labeled as Sp in Fig. 3b).
The origin of this population is not known but its DNA
content, based on propidium staining, was 6% larger than
that of G1-phase cells, suggesting that it represented cells
arrested in early S-phase rather than G1-phase and not
undergoing DNA degradation. A possible explanation of its
high γ-H2AX staining is that it reflects extensive DNA
damage associated with early apoptosis induction (Fig. 3b).
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RL90 and RL91 also induced increases in G2/M-phase
proportions of MDA-MB-231 and SKBr3 cells (Suppl.
Fig. S2B). The flow cytometry profile of MDA-MB-231
cells treated with RL90 and RL91 was similar to those of
TamR3 and TamC3 cells. However the profile for treated
SKBr3 cells showed the presence of a sub-G1-phase
population with high γ-H2AX staining, probably indicative
of apoptotic cells (Fig. 3c).
Comparison of RL90 and RL91 with topoisomerase
poisons
The S-phase selective γ-phosphorylation of H2AX in
TamC3 cells in response to RL90 or RL91 was similar
to that reported for other cells lines with camptothecin
[16], which is known to act as a poison of the enzyme
topoisomerase I, impeding DNA replication fork move-
ment and leading to formation of double-stranded DNA
breaks [17]. We therefore compared the ability of RL90,
RL91 and camptothecin, together with the topoisomerase
II poison doxorubicin [18] to inhibit cell proliferation, to
induce cell cycle changes and to change γ-H2AX staining
of TamC3 cells. The logarithmic IC50 values of RL91 for
all the MCF-7 lines correlated significantly to those of
both camptothecin (r=0.96; p<0.01) and doxorubicin (r=
0.98; p<0.01); values for RL90 were also highly correlated
(Table 1). Flow cytometry profiles for cells treated with
RL90 and RL91 were similar to that for camptothecin
except no increase in G2/M-phase occurred (Suppl.
Fig. 2C). Doxorubicin induced an increase in G2/M-phase
cells, but unlike camptothecin (Suppl. Fig. S2C), RL90
and RL 91, induced marked γ-H2AX phosphorylation in
all cells (Fig. 3d).
Camptothecin, like RL91 but unlike doxorubicin, in-
duced the formation of a minor population of TamC3 cells
with a DNA content 5% greater than that of G1-phase cells
with high staining for γ-phosphorylation of H2AX
(Fig. 3d). In MDA-MB-231 cultures, camptothecin differed
from RL90 to RL91 in the induction of a high degree of S-
phase selective γ-H2AX phosphorylation (Fig. 3c). In
SKBr3 cells, camptothecin resembled RL90 and RL91 in
the induction of a sub-G1 phase population with high γ-
H2AX expression.
Effects of RL90 and RL91 on isolated topoisomerase I
Since the above results suggested that topoisomerase I
might be a target enzyme for RL90 and RL91, we
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Fig. 2 Effects of cyclohexa-
none RL90 and RL91 in MDA-
MB-231, SKBr3, MCF-7
parental and its derived
sub-lines in proliferation.
MDA-MB-231, SKBr3, MCF-7
parental and its sub-lines were
exposed to 1 μM of RL90 and
RL91 and 10 μM of curcumin
for 3 days and cell proliferation
was measured by sulforhod-
amine B staining. Results repre-
sent percentages with respect to
untreated controls and are
shown as the mean±SEM from
three experiments. *Significant-
ly different from MCF-7 paren-
tal line (p<0.05)
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compared their ability to induce relaxation of closed
circular duplex DNA in the presence of recombinant
topoisomerase I. RL90 and RL91 could be distin-
guished from camptothecin because they did not cause
DNA cleavage (Fig. 4a). However, all three drugs
inhibited the relaxation activity of topoisomerase I,
with RL91 showing greater efficacy than RL90
(Fig. 4b).

























Fig. 3 Induction of γ-H2AX
phosphorylation following
exposure to RL90 and RL91.
Cellular immunofluorescence
(anti-γ-H2AX antibody; y-axis)
is plotted against DNA content
(propidium iodide staining;
x-axis). The upper left hand
quadrant (marked) represents
high γ-H2AX phosphorylation
and the proportion of the total is
indicated. a MCF-7 parental and
derived TamC3 and TamR3
sub-lines were either untreated
or exposed to RL90 or RL91
(10 μM) for 16 h, then fixed,
stained, and assessed by flow
cytometry for γ-H2AX staining
and DNA content. b Effect of
RL91 (10 μM) exposure time on
MCF-7 TamC3 sub-line. The
DNA content of the box marked
Sp is 6% higher than that of the
box marked G1 but shows high
γ-H2AX phosphorylation. c
Effects of camptothecin (1 μM),
RL90 (10 μM) and RL91
(10 μM) on MDA-MB-231 and
SKBr3 cells (exposure time
16 h). The DNA content of the
box marked Sp is 4% higher
than that of the box marked G1
but shows high γ-H2AX
phosphorylation. The DNA
content of the box marked Ap is
lower than that of the box
marked G1 and shows high γ-
H2AX phosphorylation, sug-
gesting an apoptotic population.
d Effect on MCF-7 TamC3 cells
of doxorubicin (500 nM for
16 h) or camptothecin (1 μM for
16 h). The DNA content of the
box marked Sp is 5% higher
than that of the box marked G1
but shows high γ-H2AX
phosphorylation
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Investigation of possible mechanisms of selective growth
inhibition by RL90 and RL91
Low expression of topoisomerase I, or low phosphory-
lation of topoisomerase I by the enzyme casein kinase-2
(CK2) have both been reported as possible mechanism
of cellular resistance to camptothecin [19, 20]. We
therefore measured expression of topoisomerase I and
CK2 (Fig. 5) in the cell lines by immunoblotting;
SKBr3 showed the lowest topoisomerase I expression
of the cell lines but all lines showed similar expression
of CK2. There was no correlation between expression
of either enzyme and sensitivity to RL90, RL91 or
camptothecin (Figs. 2, 5 and 6 and Suppl. Fig. S3). We
also determined the effect of pre-treatment with CK2
inhibitor (TBBt; 10 μM) and with a CK2 activator (1-
ethyl-4,5-dicarbamoylimidazole; 10 nM) but did not
observe changes in sensitivity with either drug (Suppl.
Fig. S4A and B; Suppl. Fig. S5A and B). Since the
ATP-binding cassette (ABC) transporter ABCG2
(BCRP) has been reported to promote resistance to
camptothecin [21, 22], we measured ABCG2 expression.
This was highest in TamR7 but expression among the
lines did not correlate with camptothecin sensitivity
(Figs. 5 and 6).
Discussion
The results show that the cyclohexanone derivatives
RL90 and RL91 selectively inhibit the proliferation of
TamC3 and TamR3, two antiestrogen-resistant MCF-7
sub-lines, as compared to the MCF-7 parental line
(Fig. 2). RL90 and RL91 also induced marked S-phase
DNA damage in TamC3 and TamR3 but little in the
parental line. MDA-MB-231 cells responded in a manner
similar to that of the MCF-7 parental line while SKBr3
cells showed intermediate effects together with marked
Untreated   Camptothecin RL90 RL91


























Table 1 Correlation coefficients of logarithmic IC50 values for RL90,
RL91, curcumin and camptothecin in MCF-7 parental and sub-lines.
Positive correlation coefficients were observed for all pairs tested.
*p<0.01
RL90 RL91 Camptothecin Doxorubicin
Curcumin 0.965* 0.974* 0.927* 0.972*
RL90 0.965* 0.925* 0.988*
RL91 0.962* 0.978*
Camptothecin 0.966*
2108 Invest New Drugs (2012) 30:2103–2112
evidence for the induction of apoptosis. The S-phase
selective action of RL90 and RL91 on TamC3 and TamR3
was similar to that induced by the topoisomerase I poison
camptothecin (Fig. 3). Flow cytometric analysis of many
of the cells treated with RL90, RL91 and camptothecin
show the presence of an early S-phase population with
high γ-H2AX staining (Sp in Fig. 3). However, this is not
observed in SKBr3 cultures but instead a sub-G1-phase
population with high γ-H2AX staining (Ap in Fig. 3) is
observed. A possible explanation is that in MCF-7 and
MDA-MB-231 cells a fraction (Sp) undergoes internu-
cleasomal DNA cleavage but no DNA degradation,
whereas in SKBr3 cells a fraction (Ap) undergoes both
internucleasomal DNA cleavage and DNA degradation.
These results indicate that RL90 and RL91 resemble
camptothecin in their induction of apoptosis.
Nevertheless, RL90 and RL91 could be distinguished from
camptothecin in studies using isolated topoisomerase I, where
all drugs inhibited the relaxation activity of topoisomerase I
but only camptothecin induced the formation of covalent
protein-DNA complexes (Fig. 4). Although other actions are
possible [10], a plausible mechanism for the cytotoxic action
of RL90 and RL91 is that they inhibit topoisomerase I in a
fashion similar to that proposed for CY13II, an
indolizinoquinoline-5,12-dione derivative [23]. On analogy
with the model proposed for CY13II, RL90 and RL91 may
stabilize a non-covalent complex involving drug, topoiso-
merase I and DNA, preventing the advancement of the DNA
replication fork and inducing DNA damage.
While the results provide a possible mechanism of
cytotoxicity for RL90 and RL91, they do not explain the
selectivity of these drugs for the TamR3 and TamC3 sub-
lines. Changes in drug sensitivity might be mediated by
differences in expression of ABCG2, a drug efflux protein
that acts to reduced intracellular concentrations of campto-
thecin [21, 22], but ABCG2 expression was found not to
correlate with sensitivity. The correlation of IC50 values for
RL90 and RL91 with that of camptothecin (Table 1)
suggests that changes in topoisomerase I content might
account for these differences, but since IC50 values also
correlated with those of doxorubicin, it may reflect induced
DNA damage by other mechanisms. Furthermore, we could
observe no correlation between camptothecin sensitivity
and topoisomerase I expression (Fig. 5), which would be
expected if camptothecin sensitivity was associated with























































Fig. 5 Effect of camptothecin and its correlation to RL compounds in
breast cancer cell lines. MDA-MB-231, SKBr3, MCF-7 parental and
its sub-lines were exposed to 111 nM camptothecin for 3 days, and
cell proliferation was measured by sulforhodamine B assay. Results
were shown as the mean±SEM from three experiments. *Significant
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Fig. 4 Suppression of topoisomerase I-mediated relaxation of super-
coiled plasmid DNA by RL compounds. a RL90 and RL91 did not
stimulate DNA cleavage mediated by topoisomerase I. No top-
oisomerase I-mediated DNA cleavage was observed in RL90 and
RL91 at 100 μM. Camptothecin is included as an example of drug-
induced in topoisomerase I mediated DNA cleavage. The gel was run
in the presence of ethidium bromide. Arrow, Nicked DNA. b RL90
and RL91 inhibit the catalytic activity of DNA topoisomerase I. DNA
relaxation assay was performed in the presence of RL90 (100 μM,
lane 5) and RL91 (100 μM, lane 6). CPT (100 μM, lane 4) and
DMSO (lane 3) was included as control. Agarose gel stained with
ethidium bromide was shown. Arrow, supercoiled DNA. LM linear
marker; SC supercoiled DNA (0.25 μg); R relaxed DNA; N Nicked
DNA; Topo topoisomerase I 1 unit (a), 0.25 units (b); CPT:
camptothecin (100 μM); RL90, 100 μM; RL91, 100 μM
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Previous studies have indicated that topoisomerase I can
be phosphorylated by CK2, PKC and cdk1 and that these
enhanced its DNA relaxation activity [25]. A high level of
CK2 activity has also been shown to be related to
camptothecin sensitivity, supporting the hypothesis that
increased topoisomerase I phosphorylation might be re-
sponsible for the sensitivity of the TamR3 and TamC3 sub-
lines [20]. However, we observed no significant correlation
between sensitivity to camptothecin and expression of CK2.
Addition to cultures of TBBt and 1-ethyl-4,5-dicarbamoy-
limidazole, which modulate CK2 activity, caused no
substantial change in sensitivity to camptothecin or RL91,
supporting the conclusion that CK2 was not responsible. A
further possible explanation for the increased sensitivity of the
TamC3 and TamR3 sub-lines is that it is a consequence of
reduced activity of Akt, since Akt is necessary to the
activation of Mre11, a component of the DNA repair complex
that forms following DNA damage [26]. Akt is minimally
phosphorylated in the MCF-7 TamR3 and TamC3 sub-lines
[5], consistent with this hypothesis. A prediction of the
hypothesis is that TamR3 and TamC3 should be hypersen-
sitive not only to camptothecin but also to other therapeutic
agents that damage DNA, a prediction that has been borne
out by studies that are currently in progress.
RL90 or RL91 are structurally related to BMHPC and
more distantly related to curcumin. It is of interest even
though the growth inhibitory activity of curcumin against
TamC3 and TamR3 is much lower than that of RL90 or
RL91, the IC50 values for curcumin correlate with RL90,
RL91 and camptothecin. The observations support the
hypothesis that curcumin has multiple cellular targets [11,
12] while RL90 and RL91 are more selective for inducing
DNA damage in S-phase cells. It may be possible to
develop further compounds with structural similarities to
curcumin but with increased selectivity for topoisomerase I
and thus greater clinical potential. Hence, these drugs
provide a platform for the further development of the class
of topoisomerase I catalytic inhibitors.
In conclusion, two tamoxifen-resistant sub-lines of the
MCF-7 cell line, one (TamR3) derived by culturing in the
presence of tamoxifen and the other (TamC3) by culturing
in the absence of estrogen, have been found to acquire
collateral sensitivity to RL90, RL91 and camptothecin. The
results suggest that the enzyme topoisomerase I is a
potential target in some sub-populations tamoxifen-
resistant breast cancer. There have been few published
trials of topoisomerase I poisons in tamoxifen-resistant











































0.9 0.7 1.0 0.9 0.6 0.6 0.3 0.4
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Tubulin
Fig. 6 Immunoblotting for top-
oisomerase I, CK2 and BCRP
antibodies. Protein level of top-
oisomerase I and CK2 for MCF-
7 sub-lines, MDA-MB-231,
SKBr3 and shown. Bands were
normalized to their respective
control, actin or tubulin, as
indicated
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Herceptin and irinotecan in treating HER2+ breast cancer.
The results raise the question of whether clinical top-
oisomerase I poisons such as irinotecan and topotecan
might be candidates for treatment of some emerging
tamoxifen-resistant breast cancers.
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